Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K
Cell Rep. 2014 7 (4): 999-1008

PMID: 24813888 · PMCID: PMC4074596 · DOI:10.1016/j.celrep.2014.04.014

MeSH Terms (22)

Adenocarcinoma Adenocarcinoma of Lung Afatinib Animals Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Cell Line, Tumor Cetuximab Drug Resistance, Neoplasm ErbB Receptors Humans Lung Neoplasms Mechanistic Target of Rapamycin Complex 1 Mice Mice, Nude Mice, Transgenic Multiprotein Complexes Mutation Quinazolines Random Allocation TOR Serine-Threonine Kinases Xenograft Model Antitumor Assays

Connections (2)

This publication is referenced by other Labnodes entities: